The stock of Vor Biopharma Inc (VOR) has seen a 24.69% increase in the past week, with a 31.17% gain in the past month, and a -11.02% decrease in the past quarter. The volatility ratio for the week is 18.26%, and the volatility levels for the past 30 days are at 11.08% for VOR. The simple moving average for the last 20 days is 22.35% for VOR’s stock, with a simple moving average of -35.67% for the last 200 days.
Is It Worth Investing in Vor Biopharma Inc (NASDAQ: VOR) Right Now?
Additionally, the 36-month beta value for VOR is -0.39. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VOR is 59.58M and currently, short sellers hold a 2.79% ratio of that float. The average trading volume of VOR on September 10, 2024 was 756.48K shares.
VOR) stock’s latest price update
The stock price of Vor Biopharma Inc (NASDAQ: VOR) has jumped by 20.04 compared to previous close of 0.91. Despite this, the company has seen a gain of 24.69% in its stock price over the last five trading days. benzinga.com reported 2024-09-06 that Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg.
Analysts’ Opinion of VOR
Many brokerage firms have already submitted their reports for VOR stocks, with Wedbush repeating the rating for VOR by listing it as a “Outperform.” The predicted price for VOR in the upcoming period, according to Wedbush is $18 based on the research report published on July 26, 2022 of the previous year 2022.
Goldman, on the other hand, stated in their research note that they expect to see VOR reach a price target of $6. The rating they have provided for VOR stocks is “Neutral” according to the report published on April 27th, 2022.
H.C. Wainwright gave a rating of “Buy” to VOR, setting the target price at $26 in the report published on December 17th of the previous year.
VOR Trading at 18.79% from the 50-Day Moving Average
After a stumble in the market that brought VOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.29% of loss for the given period.
Volatility was left at 11.08%, however, over the last 30 days, the volatility rate increased by 18.26%, as shares surge +32.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.39% lower at present.
During the last 5 trading sessions, VOR rose by +24.69%, which changed the moving average for the period of 200-days by -35.50% in comparison to the 20-day moving average, which settled at $0.9044. In addition, Vor Biopharma Inc saw -51.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VOR starting from Attar Eyal C., who sale 14,645 shares at the price of $1.39 back on Jun 03 ’24. After this action, Attar Eyal C. now owns 96,063 shares of Vor Biopharma Inc, valued at $20,357 using the latest closing price.
Stock Fundamentals for VOR
Current profitability levels for the company are sitting at:
- -10.21 for the present operating margin
- 0.61 for the gross margin
The net margin for Vor Biopharma Inc stands at -9.66. The total capital return value is set at -0.98. Equity return is now at value -78.07, with -60.16 for asset returns.
Based on Vor Biopharma Inc (VOR), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -3.08. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -62.75.
Currently, EBITDA for the company is -122.54 million with net debt to EBITDA at 0.35. When we switch over and look at the enterprise to sales, we see a ratio of 2.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.54.
Conclusion
In conclusion, Vor Biopharma Inc (VOR) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
